Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference

DURHAM, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3, 2018 at 1:05 p.m. ET at the InterContinental New York Barclay Hotel.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001), currently being evaluated in the AdAPT trial for the treatment of adenovirus in pediatric transplant recipients; CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT:Investor Relations:                             Michelle LaSpaluto 919 972-7115 [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200

Media: Laurie Masonson W2O Group [email protected]   917 459-6164

You May Also Be Interested In

• The America Review of Books Champions a New Standard of Literary Integrity, Author Advocacy, and the American Storytelling Tradition
• 12B SPORTS and VR46 Racing Team Bring Sung Kang into the World of MotoGP
• Freedom Holding Marks New Türkiye Milestone as Freedom Yatırım Secures Brokerage License